💰 Financial Performance

Revenue Growth by Segment

Total income grew by 123.38% YoY, reaching INR 110.61 Cr in FY 2024-25 compared to INR 49.52 Cr in FY 2023-24. The company operates in a single segment: Pharmaceuticals.

Profitability Margins

Operating Profit Margin improved to -8.75% in FY 2024-25 from -30.94% in FY 2023-24. Net Profit Margin remained stable at -9.0% YoY.

EBITDA Margin

Operating Profit Margin (EBIT/Revenue) was -8.75% in FY 2024-25, showing a significant recovery from -30.94% in the previous year.

⚙️ Operational Drivers

Raw Materials

Bulk drugs and Active Pharmaceutical Ingredients (APIs) are the primary raw materials used for formulations.

Raw Material Costs

The company identified continuous increases in raw material input costs as a significant challenge that pressures profitability margins.

Manufacturing Efficiency

Inventory turnover ratio improved by 104.8% YoY to 6.39 times, indicating significantly better stock movement efficiency.

📈 Strategic Growth

Growth Strategy

Growth is targeted through the development of new products via research and development and expanding export market reach by participating in international trade shows.

Products & Services

Bulk drugs (APIs) and medicinal formulations.

Brand Portfolio

Oxygenta Pharmaceutical Limited.

Market Expansion

Active participation in Exports Industry Trade Shows to reach international markets.

🌍 External Factors

Industry Trends

The Indian pharmaceutical market is the 3rd largest by volume globally. Trends show a shift toward high-value API production and generic drug supply chain integration.

Competitive Landscape

Faces intense competition from market players, new technological shifts, and stringent patent laws.

Competitive Moat

Moat is based on expertise in Active Pharmaceutical Ingredients (APIs) and a strong position in the global generic drug supply chain.

Macro Economic Sensitivity

Highly sensitive to domestic and overseas economic conditions, government policy changes, and inflationary pressures.

Geopolitical Risks

Global slowdowns and international trade policies are cited as factors that could bound the company's performance.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by stringent patent laws, government regulations, and Ind-AS accounting standards.

⚠️ Risk Analysis

Key Uncertainties

Technological obsolescence and competition from new market entrants pose risks to the company's 123% revenue growth trajectory.

Technology Obsolescence Risk

Identified as a risk; the company is attempting to counter new technologies through R&D and process improvements.

Credit & Counterparty Risk

Debtors turnover ratio decreased by 72.59% to 22.61 times, indicating a significant slowdown in receivables collection and increased credit risk.